Blood cancers

Kymriah turns 5: long term trial follow-up in relapsed/refractory DLBCL

Sponsored by Novartis Pharmaceuticals Australia Pty Ltd

Chimeric antigen receptor T-cell (CAR-T) therapy is a promising treatment option for a broad range of cancers.1 The CAR-T therapies that have advanced the furthest in clinical trials are those targeting CD-19 expressing cells in acute and non-acute B-cell leukaemias and B-cell non-Hodgkin lymphomas.1 In 2020, the Australian government expanded its funding of  access to ...

Already a member?

Login to keep reading.

© 2021 the limbic